公开(公告)号：US07923204B2

公开(公告)日：2011-04-12

申请号：US10554433

申请日：2004-04-22

申请人： Warren E. Glaab ,  Thomas R. Skopek ,  Katerina Vlasakova ,  Judith E. Miller

发明人： Warren E. Glaab ,  Thomas R. Skopek ,  Katerina Vlasakova ,  Judith E. Miller

IPC分类号： C12Q1/00 ,  C12Q1/02 ,  C12Q1/18

CPC分类号： C12N15/01 ,  C12N15/1024 ,  C12Q1/18 ,  G01N33/5014 ,  G01N2333/255

摘要： Disclosed herein is a novel forward mutation assay based on 5-fluorouracil (5-FU) resistance which utilizes a strain of Salmonella typhimurium derived from the Ames strain TA100. More specifically, the invention provides a high throughput alternative to the standard Ames mutation assay for the evaluation of the genotoxicity activity of compounds during an early stage of the drug development process. The invention also identifies the upp locus as a mutational target that is capable of detecting a diverse spectrum of mutagenic events and further describes a S. typhimurium tester strain, designated FU100 (his+, rfa, ΔuvrB, pkM101, 5-fluorouridine resistant) for use in the assay of the invention.

摘要翻译： 本文公开了基于5-氟尿嘧啶（5-FU）抗性的新型正向突变测定法，其利用源自Ames菌株TA100的鼠伤寒沙门氏菌菌株。 更具体地，本发明提供了用于在药物开发过程的早期阶段评估化合物的基因毒性活性的标准Ames突变测定法的高通量替代物。 本发明还将upp基因座识别为能够检测多种诱变事件的突变靶，并进一步描述了命名为FU100（his +，rfa，＆Dgr; uvrB，pkM101,5-氟尿苷抗性）的鼠伤寒沙门氏菌菌株 用于本发明的测定中。